The Medicines Company (NASDAQ:MDCO) shares fell 6.7% during trading on Tuesday . The company traded as low as $25.25 and last traded at $25.67. 2,097,075 shares were traded during mid-day trading, an increase of 81% from the average session volume of 1,156,107 shares. The stock had previously closed at $27.51.

A number of brokerages recently commented on MDCO. Oppenheimer set a $50.00 target price on The Medicines and gave the company a “buy” rating in a research note on Monday. Zacks Investment Research upgraded The Medicines from a “sell” rating to a “buy” rating and set a $31.00 price target on the stock in a research report on Tuesday, January 2nd. ValuEngine upgraded The Medicines from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. Citigroup upgraded The Medicines from a “sell” rating to an “outperform” rating in a research report on Thursday, November 30th. Finally, Jefferies Group reiterated a “buy” rating and issued a $54.00 price target on shares of The Medicines in a research report on Thursday, October 26th. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $52.56.

The stock has a market capitalization of $1,870.00, a PE ratio of -2.81 and a beta of 0.71. The company has a current ratio of 2.31, a quick ratio of 1.79 and a debt-to-equity ratio of 3.42.

The Medicines (NASDAQ:MDCO) last announced its earnings results on Wednesday, October 25th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($1.37) by $0.95. The company had revenue of $16.87 million for the quarter, compared to analysts’ expectations of $26.06 million. The Medicines had a negative return on equity of 174.68% and a negative net margin of 767.94%. The business’s revenue for the quarter was down 55.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.64) earnings per share. equities research analysts expect that The Medicines Company will post -8.86 earnings per share for the current fiscal year.

In other The Medicines news, insider Fredric N. Eshelman bought 200,000 shares of the firm’s stock in a transaction dated Friday, December 8th. The shares were bought at an average price of $26.56 per share, for a total transaction of $5,312,000.00. Following the completion of the acquisition, the insider now owns 1,028,383 shares of the company’s stock, valued at $27,313,852.48. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Alexander J. Denner bought 170,000 shares of the firm’s stock in a transaction dated Wednesday, November 29th. The shares were acquired at an average price of $30.03 per share, for a total transaction of $5,105,100.00. Following the acquisition, the director now directly owns 6,663 shares of the company’s stock, valued at approximately $200,089.89. The disclosure for this purchase can be found here. 8.22% of the stock is currently owned by corporate insiders.

Several hedge funds have recently made changes to their positions in MDCO. Schwab Charles Investment Management Inc. boosted its holdings in The Medicines by 3.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 302,528 shares of the company’s stock valued at $11,500,000 after acquiring an additional 8,900 shares during the last quarter. Neuberger Berman Group LLC boosted its holdings in The Medicines by 100.0% in the second quarter. Neuberger Berman Group LLC now owns 18,000 shares of the company’s stock valued at $684,000 after acquiring an additional 9,000 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in The Medicines by 10.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,753 shares of the company’s stock valued at $105,000 after acquiring an additional 264 shares during the last quarter. Swiss National Bank boosted its holdings in The Medicines by 1.8% in the second quarter. Swiss National Bank now owns 118,750 shares of the company’s stock valued at $4,514,000 after acquiring an additional 2,100 shares during the last quarter. Finally, Riverhead Capital Management LLC boosted its holdings in The Medicines by 74.0% in the second quarter. Riverhead Capital Management LLC now owns 6,960 shares of the company’s stock valued at $264,000 after acquiring an additional 2,960 shares during the last quarter.

WARNING: This report was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.thecerbatgem.com/2018/01/17/the-medicines-mdco-trading-down-6-7.html.

About The Medicines

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.